Literature DB >> 27596095

Partially Saturated Bicyclic Heteroaromatics as an sp(3) -Enriched Fragment Collection.

David G Twigg1, Noriyasu Kondo1,2, Sophie L Mitchell1, Warren R J D Galloway1, Hannah F Sore1, Andrew Madin3, David R Spring4.   

Abstract

Fragment-based lead generation has proven to be an effective means of identifying high-quality lead compounds for drug discovery programs. However, the fragment screening sets often used are principally comprised of sp(2) -rich aromatic compounds, which limits the structural (and hence biological) diversity of the library. Herein, we describe strategies for the synthesis of a series of partially saturated bicyclic heteroaromatic scaffolds with enhanced sp(3) character. Subsequent derivatization led to a fragment collection featuring regio- and stereo-controlled introduction of substituents on the saturated ring system, often with formation of new stereocenters.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  drug design; drug discovery; fused-ring systems; nitrogen heterocycles; synthetic methods

Year:  2016        PMID: 27596095      PMCID: PMC5091628          DOI: 10.1002/anie.201606496

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


Fragment‐based drug discovery (FBDD) is a well‐established method for generating high‐quality hits and leads.1 The approval of the B‐Raf kinase inhibitor vemurafenib (Zelboraf) in 20112 and the Bcl‐2 inhibitor venetoclax (Venclexta) in 2016,3 coupled with the ongoing evaluation of over 20 candidates in clinical trials,4 validates this approach as a complementary strategy to other hit‐discovery techniques such as high‐throughput screening.5 While the growing prevalence of fragment‐based approaches is encouraging, evaluation of many existing fragment libraries shows a predominance of (hetero)aromatic, “flat” compounds, with a deficiency of chiral, sp3‐rich examples.6, 7 Studies by Ritchie et al.8 and Lovering et al.9 demonstrate improvements in project progression by, for example, increasing the fraction of sp3 centers within molecules or restricting the number of aromatic rings. Furthermore, computational analysis demonstrates that greater 3D conformational character is observed in compounds that have been clinically evaluated in humans, compared to those found in commercial libraries.10 This indicates the importance of sp3‐richness in both the design of screening collections and the subsequent development of hits to leads. Examples of previous studies aiming to synthesize collections of sp3‐enriched fragments have been limited. Diversity‐oriented synthesis7, 11 and natural product derivatives12 have been used to generate 3D fragment collections, but there remains an unmet need to access new scaffold types. Recently there have been calls13 for new approaches and methodologies for designing fragments with multiple synthetically accessible growth vectors in three dimensions, to allow rapid and efficient elaboration of hits to leads after initial screening, with some early success.14 With these points in mind, the study described herein was aimed at developing efficient synthetic routes to a series of partially saturated bicyclic heteroaromatic (PSBH) fragments with enhanced sp3 content relative to existing fragment libraries. Compounds featuring PSBHs have been shown to display bioactivity against a range of targets (Figure 1),15 and so a series of related fragments might be expected to serve effectively as a screening collection for FBDD applications.
Figure 1

Selected examples of bioactive compounds containing functionalized partially saturated bicyclic heteroaromatics (highlighted in red).

Selected examples of bioactive compounds containing functionalized partially saturated bicyclic heteroaromatics (highlighted in red). The targets of this study featured a variable aromatic heterocycle fused to a partially saturated carbocycle. The heterocycle could bear either a polar (e.g., amino) group, which should greatly enhance aqueous solubility, a property necessary for fragment screening at higher concentrations,7, 14 or alternatively a hydrophobic (e.g., chloro) group, which can forge key interactions with protein targets.16 The synthetic route (Scheme 1) employed a modular and divergent approach, using simple cross‐coupling and alkylation reactions to install a pair of terminal olefins that could be reliably cyclized through ring‐closing metathesis (RCM).17 This allowed excellent control of the carbocycle ring size and the position and orientation of the resultant endocyclic olefin growth vector, which could undergo subsequent functionalization to produce a range of fragments suitable for screening and/or further elaboration.
Scheme 1

General synthetic strategy toward PSBH scaffolds 1 and subsequent incorporation of new functionalities (2) or rings (3).

General synthetic strategy toward PSBH scaffolds 1 and subsequent incorporation of new functionalities (2) or rings (3). We selected pyrazole and pyridine as representative aromatic heterocycles. Whilst previous studies have shown the synthesis of related structures,18 they have incorporated less control over the position of the olefin and do not feature the amino group found in many of our compounds. Furthermore, there are only very few examples where the olefin is used as a branch point and further functionalized beyond simple reduction.15a, 19 Starting from readily available 3‐nitro‐1H‐pyrazole (4), 2‐(trimethylsilyl)ethoxymethyl (SEM) protection, selective iodination, and subsequent Suzuki coupling with potassium vinyltrifluoroborate gave vinyl derivative 7 a (Table 1). Deprotection followed by N‐alkylation with an alkyl bromide of varying C‐chain length provided metathesis precursors 9 a–c, which upon treatment with either Grubbs’ or Hoveyda‐Grubbs’ 2nd generation catalysts yielded the desired scaffolds 10 a–c. Inclusion of further heteroatoms in the formation of medium‐sized partially saturated rings was achieved through treatment of vinyl intermediate 8 a with either tosylate 11 (leading, after RCM, to O‐containing fragment 10 d), or 3‐Boc‐1,2,3‐oxathiazolidine 2,2‐dioxide 12, which gave access to the N‐containing scaffold 10 e after allylation and metathesis. Use of a different Suzuki coupling partner gave methyl‐substituted product 7 f, which could be elaborated to PSBH fragment 10 f. Alternatively, direct allylation at the C‐5 position of SEM‐protected intermediate 5 could be achieved upon treatment with lithium diisopropylamide (LDA) and allyl bromide. This led, in an analogous way, to scaffolds 10 g–h with non‐conjugated olefins.
Table 1

Synthesis of pyrazole‐based PSBH scaffolds.

Step
mRXA (7)B (8)[c] C (9)[d] D (10)[g]
a 0H 85 %[a] 80 %55 %45 %[h]
b 0H 86 %84 %
c 0H 55 %89 %
d 0H 59 %[e] 65 %
e 0H 29 %[f] 83 %
f 0Me 76 %[a] 69 %44 %90 %
g 1H 61 %[b] 82 %70 %93 %
h 1H 36 %59 %[h]

Reaction conditions: [a] R′‐BF3K (1.5 equiv), Pd(dppf)Cl2⋅CH2Cl2 (5 mol %), K2CO3 (3.0 equiv), THF/H2O, 70 °C. [b] 5 (1.0 equiv), LDA (1.2 equiv), CuBr (20 mol %), allyl bromide (1.2 equiv), THF, −78 °C to RT. [c] TFA, CH2Cl2, RT. [d] NaH (1.5 equiv), alkyl bromide (1.5 equiv), THF or DMF, 70 °C. [e] NaH (1.5 equiv), 11 (1.5 equiv), THF, 70 °C. [f] 12 (2.0 equiv), K2CO3 (3.0 equiv), DMF, RT, 43 %; then NaH (1.5 equiv), allyl iodide (1.5 equiv), DMF, RT, 68 %. [g] Grubbs II (10 mol %), CH2Cl2, 40 °C. [h] Hoveyda‐Grubbs II (10 mol %), toluene, 110 °C or CH2Cl2, RT. THF=tetrahydrofuran, TFA=trifluoroacetic acid, DMF=N,N‐dimethylformamide.

Synthesis of pyrazole‐based PSBH scaffolds. Reaction conditions: [a] R′‐BF3K (1.5 equiv), Pd(dppf)Cl2CH2Cl2 (5 mol %), K2CO3 (3.0 equiv), THF/H2O, 70 °C. [b] 5 (1.0 equiv), LDA (1.2 equiv), CuBr (20 mol %), allyl bromide (1.2 equiv), THF, −78 °C to RT. [c] TFA, CH2Cl2, RT. [d] NaH (1.5 equiv), alkyl bromide (1.5 equiv), THF or DMF, 70 °C. [e] NaH (1.5 equiv), 11 (1.5 equiv), THF, 70 °C. [f] 12 (2.0 equiv), K2CO3 (3.0 equiv), DMF, RT, 43 %; then NaH (1.5 equiv), allyl iodide (1.5 equiv), DMF, RT, 68 %. [g] Grubbs II (10 mol %), CH2Cl2, 40 °C. [h] Hoveyda‐Grubbs II (10 mol %), toluene, 110 °C or CH2Cl2, RT. THF=tetrahydrofuran, TFA=trifluoroacetic acid, DMF=N,N‐dimethylformamide. A similar approach was used to generate PSBH scaffolds from pyridine 13 (Table 2). Attempts to mask the 2‐amino group as a nitro group proved ineffective since, despite successful cross‐coupling reactions, the 2‐nitropyridines were unstable to strong base and did not undergo the desired alkylations at the 4‐methyl position. Mono‐Boc protection was also unsuitable due to poor yields in the cross‐coupling step, possibly due to catalyst chelation. The 2‐amino group could be rendered synthetically tractable, however, either through bis‐Boc protection or through substitution with a 2‐chloro group, which itself can serve as a synthetic handle.20
Table 2

Synthesis of pyridine‐based PSBH scaffolds.

Step
RnR1 R2 A (15)[b] B (16)[e] C (17)[f]
a Boc2N0HH85 %60 %95 %
b Boc2N0HMe69 %94 %
c Boc2N0HCF3 77 %54 %
d Boc2N0MeH87 %60 %94 %
e Boc2N0PhH92 %68 %83 %
f Boc2N1HH78 %[c] 41 %65 %
g Cl1HH73 %[d] 79 %91 %

Reaction conditions: [a] Boc2O (2.5 equiv), DMAP (0.1 equiv), THF, 70 °C. [b] R′‐BF3K or R′‐B(MIDA) (1.5 equiv), Pd(dppf)Cl2⋅CH2Cl2 (10 mol %), K2CO3 (3.0 equiv), THF/H2O, 70 °C. [c] Allyltributyltin (1.1 equiv), Pd(PPh3)4 (10 mol %), KF (2 equiv), toluene, 110 °C. [d] i‐PrMgCl.LiCl (1.5 equiv), allyl bromide (1.2 equiv), THF, −15 °C to RT. [e] LDA (1.2 equiv), alkyl bromide (1.5 equiv), THF, −78 °C to RT. [f] Grubbs II (5 mol %), CH2Cl2, 40 °C. DMAP=4‐dimethylaminopyridine.

Synthesis of pyridine‐based PSBH scaffolds. Reaction conditions: [a] Boc2O (2.5 equiv), DMAP (0.1 equiv), THF, 70 °C. [b] R′‐BF3K or R′‐B(MIDA) (1.5 equiv), Pd(dppf)Cl2CH2Cl2 (10 mol %), K2CO3 (3.0 equiv), THF/H2O, 70 °C. [c] Allyltributyltin (1.1 equiv), Pd(PPh3)4 (10 mol %), KF (2 equiv), toluene, 110 °C. [d] i‐PrMgCl.LiCl (1.5 equiv), allyl bromide (1.2 equiv), THF, −15 °C to RT. [e] LDA (1.2 equiv), alkyl bromide (1.5 equiv), THF, −78 °C to RT. [f] Grubbs II (5 mol %), CH2Cl2, 40 °C. DMAP=4‐dimethylaminopyridine. Bis‐Boc substrate 14 (prepared in one step from 13) was functionalized at the 5‐position using either Suzuki coupling (for vinyl substituents) or Stille coupling (for allyl substituents) to produce intermediates 15 a,d–f. Treatment with LDA and trapping of the resultant anion with a variable alkyl bromide electrophile gave a range of metathesis substrates (16 a–f), which under standard ring‐closing metathesis conditions yielded PSBH scaffolds 17 a–f. The 2‐chloro substrate 18 could be allylated in the 5‐position by using an excess of i‐PrMgCl⋅LiCl and trapping the resultant organometallic intermediate with allyl bromide. Allylation at the 4‐methyl position and RCM gave scaffold 17 g in superior yields. Following PSBH synthesis, a series of simple one‐, two‐, or three‐step functionalizations were performed on selected pyrazole and pyridine scaffolds to demonstrate the synthetic utility of the olefin π‐bond as a growth vector and to generate a variety of new stereocenters (Scheme 2).
Scheme 2

Functionalization of PSBH scaffolds. For reaction conditions, see the Supporting Information.

Functionalization of PSBH scaffolds. For reaction conditions, see the Supporting Information. Catalytic hydrogenation of nitropyrazoles 10 a–d,f served to reduce both the olefin π‐bond and the nitro group in moderate to good yields, revealing the latent amino functionality and, in the case of 19 f, creating a new stereocenter. Other one‐step reactions include aziridination, dibromination, allylic oxidation dihydroxylation, difluorocyclopropanation, hydroxybromination, epoxidation, and hydroboration (20–28) to introduce functionalities at the 4‐, 5‐ and 6‐positions of the fused pyrazole systems. Demonstrating that these initial products can serve as intermediates to other fragments, the products of hydroboration can react further to incorporate Br, F, and N substituents (30–33), whilst epoxide 26 can be opened by nucleophiles such as fluoride and hydride to form fluorohydrin 35 and alcohol 36. Whilst the yields of some reactions were modest, sufficient material was obtained for full characterization and future screening campaigns. The pyridine‐based scaffolds 17 a–g can undergo a similar range of transformations. Catalytic hydrogenation and subsequent acid‐mediated deprotection of bis‐Boc compounds 17 a–f generated novel fragments, many of which include new stereocenters (37 a–f). Aziridination, dibromination, dihydroxylation, hydroboration, α‐bromoketone formation, and hydroxybromination were also carried out (38–43). Further reactions included amino‐alcohol (44) and epoxide (45) formation, both from bromohydrin 43. 3‐Chloro fragments 46–51 could also be readily accessed using similar conditions. Calculation of a range of physicochemical properties was carried out on all of the PSBH products. Almost all fragments were shown to conform to the so‐called “Rule of Three”, a set of criteria commonly associated with greater hit rates in fragment screening collections.21 Of particular note are the low mean values for molecular weight (190), SlogP (1.45), and “fraction aromatic” (0.43) and the high mean number of chiral centres (0.88), especially when compared to existing commercial libraries (Table 3).
Table 3

Mean physicochemical properties of fragment collections.

Property[a] Ideal Range[b] This workChembridgeMaybridge

[a] MW=molecular weight, PSA=polar surface area, HBA=number of hydrogen‐bond acceptors, HBD=number of hydrogen‐bond donors, HAC=heavy atom count, RBC=rotatable bond count. [b] Based on the guidelines used by Astex Pharmaceuticals.14, 21 Green: within ideal range, orange: at extreme of ideal range, red: outside ideal range. See the Supporting Information for further details.

Mean physicochemical properties of fragment collections. [a] MW=molecular weight, PSA=polar surface area, HBA=number of hydrogen‐bond acceptors, HBD=number of hydrogen‐bond donors, HAC=heavy atom count, RBC=rotatable bond count. [b] Based on the guidelines used by Astex Pharmaceuticals.14, 21 Green: within ideal range, orange: at extreme of ideal range, red: outside ideal range. See the Supporting Information for further details. In conclusion, we have developed simple, scalable routes to a series of partially saturated pyrazole‐ and pyridine‐based scaffolds that can readily undergo a range of synthetic transformations to generate a collection of sp3‐rich fragments, which are suitable for use either as screening members in a library or as intermediates to “higher‐content fragments”. The compounds adhere to recognized guidelines for fragment physicochemical properties, whilst displaying enhanced sp3 character and greater chirality, and providing a range of three‐dimensional growth vectors for synthetic development. It is envisioned that the strategy could be applied to a vast range of analogous scaffolds with varied heterocycles and substituents and that several of the functionalization reactions detailed in Scheme 2 could be rendered asymmetric based on related precedents.19, 22 Dedicated to Professor Stuart L. Schreiber on the occasion of his 60th birthday As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re‐organized for online delivery, but are not copy‐edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors. Supplementary Click here for additional data file.
  33 in total

1.  Experiences in fragment-based lead discovery.

Authors:  Roderick E Hubbard; James B Murray
Journal:  Methods Enzymol       Date:  2011       Impact factor: 1.600

2.  Synthesis of allylated quinolines/isoquinolines via palladium-catalyzed cyclization-allylation of azides and allyl methyl carbonate.

Authors:  Jiang Luo; Zhibao Huo; Jun Fu; Fangming Jin; Yoshinori Yamamoto
Journal:  Org Biomol Chem       Date:  2015-03-21       Impact factor: 3.876

3.  Fragment-based lead discovery grows up.

Authors:  Monya Baker
Journal:  Nat Rev Drug Discov       Date:  2013-01       Impact factor: 84.694

4.  A diversity-oriented synthesis of bicyclic cis-dihydroarenediols, cis-4-hydroxyscytalones, and bicyclic conduritol analogues.

Authors:  Parag Mukherjee; Soumya J Singha Roy; Tarun K Sarkar
Journal:  Org Lett       Date:  2010-06-04       Impact factor: 6.005

5.  Enantio- and regioselective epoxidation of olefinic double bonds in quinolones, pyridones, and amides catalyzed by a ruthenium porphyrin catalyst with a hydrogen bonding site.

Authors:  Philipp Fackler; Stefan M Huber; Thorsten Bach
Journal:  J Am Chem Soc       Date:  2012-07-23       Impact factor: 15.419

6.  Domino reaction involving the Bestmann-Ohira reagent and α,β-unsaturated aldehydes: efficient synthesis of functionalized pyrazoles.

Authors:  Shakir Ahamad; Ashis Kumar Gupta; Ruchir Kant; Kishor Mohanan
Journal:  Org Biomol Chem       Date:  2015-02-07       Impact factor: 3.876

Review 7.  Vemurafenib: the first drug approved for BRAF-mutant cancer.

Authors:  Gideon Bollag; James Tsai; Jiazhong Zhang; Chao Zhang; Prabha Ibrahim; Keith Nolop; Peter Hirth
Journal:  Nat Rev Drug Discov       Date:  2012-10-12       Impact factor: 84.694

8.  Escape from flatland: increasing saturation as an approach to improving clinical success.

Authors:  Frank Lovering; Jack Bikker; Christine Humblet
Journal:  J Med Chem       Date:  2009-11-12       Impact factor: 7.446

9.  Nucleophilic ortho-allylation of pyrroles and pyrazoles: an accelerated Pummerer/thio-Claisen rearrangement sequence.

Authors:  Andrew J Eberhart; Claudio Cicoira; David J Procter
Journal:  Org Lett       Date:  2013-07-15       Impact factor: 6.005

10.  Partially Saturated Bicyclic Heteroaromatics as an sp(3) -Enriched Fragment Collection.

Authors:  David G Twigg; Noriyasu Kondo; Sophie L Mitchell; Warren R J D Galloway; Hannah F Sore; Andrew Madin; David R Spring
Journal:  Angew Chem Int Ed Engl       Date:  2016-09-06       Impact factor: 15.336

View more
  14 in total

1.  Evaluation of 3-Dimensionality in Approved and Experimental Drug Space.

Authors:  Kathleen E Prosser; Ryjul W Stokes; Seth M Cohen
Journal:  ACS Med Chem Lett       Date:  2020-05-18       Impact factor: 4.345

2.  Metal Complexes for Therapeutic Applications.

Authors:  Johannes Karges; Ryjul W Stokes; Seth M Cohen
Journal:  Trends Chem       Date:  2021-04-14

3.  Partially Saturated Bicyclic Heteroaromatics as an sp(3) -Enriched Fragment Collection.

Authors:  David G Twigg; Noriyasu Kondo; Sophie L Mitchell; Warren R J D Galloway; Hannah F Sore; Andrew Madin; David R Spring
Journal:  Angew Chem Int Ed Engl       Date:  2016-09-06       Impact factor: 15.336

4.  Divergent Synthesis and Real-Time Biological Annotation of Optically Active Tetrahydrocyclopenta[c]pyranone Derivatives.

Authors:  Shawn D Nelson; Mathias J Wawer; Stuart L Schreiber
Journal:  Org Lett       Date:  2016-12-07       Impact factor: 6.005

5.  Design and Synthesis of 56 Shape-Diverse 3D Fragments.

Authors:  Thomas D Downes; S Paul Jones; Hanna F Klein; Mary C Wheldon; Masakazu Atobe; Paul S Bond; James D Firth; Ngai S Chan; Laura Waddelove; Roderick E Hubbard; David C Blakemore; Claudia De Fusco; Stephen D Roughley; Lewis R Vidler; Maria Ann Whatton; Alison J-A Woolford; Gail L Wrigley; Peter O'Brien
Journal:  Chemistry       Date:  2020-07-08       Impact factor: 5.236

6.  Demonstration of the utility of DOS-derived fragment libraries for rapid hit derivatisation in a multidirectional fashion.

Authors:  Sarah L Kidd; Elaine Fowler; Till Reinhardt; Thomas Compton; Natalia Mateu; Hector Newman; Dom Bellini; Romain Talon; Joseph McLoughlin; Tobias Krojer; Anthony Aimon; Anthony Bradley; Michael Fairhead; Paul Brear; Laura Díaz-Sáez; Katherine McAuley; Hannah F Sore; Andrew Madin; Daniel H O'Donovan; Kilian V M Huber; Marko Hyvönen; Frank von Delft; Christopher G Dowson; David R Spring
Journal:  Chem Sci       Date:  2020-05-14       Impact factor: 9.825

7.  Synthesis and Demonstration of the Biological Relevance of sp3 -rich Scaffolds Distantly Related to Natural Product Frameworks.

Authors:  Daniel J Foley; Philip G E Craven; Patrick M Collins; Richard G Doveston; Anthony Aimon; Romain Talon; Ian Churcher; Frank von Delft; Stephen P Marsden; Adam Nelson
Journal:  Chemistry       Date:  2017-10-06       Impact factor: 5.236

8.  Divergent Synthesis of Cyclopropane-Containing Lead-Like Compounds, Fragments and Building Blocks through a Cobalt Catalyzed Cyclopropanation of Phenyl Vinyl Sulfide.

Authors:  Stephen J Chawner; Manuel J Cases-Thomas; James A Bull
Journal:  European J Org Chem       Date:  2017-09-11

Review 9.  Recent Applications of Diversity-Oriented Synthesis Toward Novel, 3-Dimensional Fragment Collections.

Authors:  Sarah L Kidd; Thomas J Osberger; Natalia Mateu; Hannah F Sore; David R Spring
Journal:  Front Chem       Date:  2018-10-16       Impact factor: 5.221

Review 10.  Fragment-based drug discovery: opportunities for organic synthesis.

Authors:  Jeffrey D St Denis; Richard J Hall; Christopher W Murray; Tom D Heightman; David C Rees
Journal:  RSC Med Chem       Date:  2020-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.